P2631 - Assessment of the Inclusion of Female, Racial/ethnic Minority and Older Individuals in Inflammatory Bowel Disease Clinical Trials

Loren Rabinowitz, MD¹, Danielle Rabinowitz, MD², Emily M. Silver, MA³, Amy S. Oxentenko, MD, FACG⁴, Kevin Williams, BA⁵, Julie K. Silver, ^6
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; ²Boston Children's Hospital, Boston, MA; ³University of Chicago, Chicago, IL; ⁴Mayo Clinic, Rochester, MN; ⁵Massachusetts General Hospital, Boston, MA; ⁶Harvard Medical School, Boston, MA

Introduction: Despite recent focus on inclusion of female, racial/ethnic minority, and older participants in clinical trials, there continues to be a lack of equitable representation of these groups in published data. Inflammatory bowel disease (IBD), once thought to be primarily a disease of non-Hispanic white patients, has seen rapid epidemiologic shifts in recent decades, with rising incidence in those from racial and ethnic minority groups and across the globe. In this study, we evaluated the inclusion of participants based on sex, race/ethnicity, and age in United States (US) based IBD clinical trials.

Methods: We performed a cross-sectional analysis of all patients included in US-based, interventional studies in IBD as reported in the National Institute of Health (NIH) ClinicalTrials.gov online database registry during a twenty-year time period from July 1, 2000 through July 1, 2020.

Results: Of the 146 included studies, 51.6% of participants were female (although they comprise approximately 55.0% of patients with IBD) (Figure 1). Gender data was available for all included studies. Pregnant and breastfeeding females were excluded from 59.5% of studies. Participant race was reported in 43.2% of trials (n=63), while ethnicity was reported in only 28.8% (n=42) of studies. Among the studies reporting race, 87.3% of participants were white, 7.6% were reported as Asian, and 3.3% were Black or African-American. Of the trials with ethnicity data, 4.1% of participants were identified as Hispanic (Figure 2). All studies reported on patient age. However, patients over 65 years were included in only 35.5% of trials of adult patients ( >=18 years) (n=52), and only 1 trial included patients >=85 years old. In trials of adult patients, the weighted mean age was 42 years.

Discussion: We identified that relative to the US IBD prevalence data, female patients were relatively underrepresented in US-based clinical trials. Members of racial and ethnic minority groups were also underrepresented, particularly Black or African-American participants and those of Hispanic ethnicity. The majority of trials did not report data on race and ethnicity, highlighting the need for greater efforts in reporting this demographic information moving forward. Older individuals were also poorly represented in the data, making it challenging to extrapolate medication and device safety and efficacy for this population.


Figure: Figure 1: Inclusion of female participants in IBD clinical trials
Figure 2: Inclusion of participants by race/ethnicity in IBD clinical trials


Disclosures:
Loren Rabinowitz indicated no relevant financial relationships.
Danielle Rabinowitz indicated no relevant financial relationships.
Emily Silver indicated no relevant financial relationships.
Amy Oxentenko indicated no relevant financial relationships.
Kevin Williams indicated no relevant financial relationships.
Julie Silver indicated no relevant financial relationships.


Loren Rabinowitz, MD¹, Danielle Rabinowitz, MD², Emily M. Silver, MA³, Amy S. Oxentenko, MD, FACG⁴, Kevin Williams, BA⁵, Julie K. Silver, ⁶. P2631 - Assessment of the Inclusion of Female, Racial/ethnic Minority and Older Individuals in Inflammatory Bowel Disease Clinical Trials, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.